Bringing the Oncology Community Together
Giants of Cancer Care 2015
Head & Neck Cancers
FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive Glioblastoma
Read More >>
View Free CME from PER >>
FDA Approves Lenvatinib in Differentiated Thyroid Cancer
Sherman Says Lenvatinib Approval “Likely” as FDA Decision Date Nears
Minimally Invasive Esophagectomy Improves Outcomes, But Remains Underutilized
Molecular Markers Emerge in the Diagnosis of Thyroid Cancer
Three Experts Discuss the Use of Cetuximab in Head and Neck Cancers
View More >>
See the latest in research and cutting edge developments from our partner institutions
- A Network of Your Peers
View more >>
Investigational Therapies for Thyroid Cancer
Frontline Treatment Selection in RAI-Refractory DTC
Optimizing Treatment With Lenvatinib in Thyroid Cancer
Lenvatinib in RAI-Refractory Thyroid Cancer
Importance of Multidisciplinary Thyroid Cancer Care
In this discussion, panelists explore the importance of multidisciplinary care for patients with locally advanced or metastatic thyroid cancer.
Treatment Selection in Advanced MTC
In this segment, panelists discuss the frontline treatment selection for patients with advanced medullary thyroid cancer who are not candidates for surgery.
Medullary Thyroid Cancer: Advances and Challenges
Moderated by Ezra Cohen, MD, this panel discussion includes expert perspectives from Eric J. Sherman, MD, Steven I. Sherman, MD, R. Michael Tuttle, MD, and Lori J. Wirth, MD.
8th Annual Multidisciplinary Symposium on Head and Neck Cancer: Medical Crossfire
CME activity worth 2.0 CME credits led by James Tate Thigpen, MD.
Most Popular Right Now
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.